Tremelimumab (anti-CTLA-4)
Tremelimumab (Ticilimumab, CP-675,206) is a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of activated T lymphocytes.
Supplier | Selleck Chemicals |
---|---|
Product # | A2021 |
Sku # | A2021-1mg |
Pricing | 1mg, $239.00 |